This message was sent to AIM, FAB, Health Systems, INE, IAP, LHD Health Officers, LHD Medical Directors, MACI, MACI 2, PH Imms Leads, MCIR Region Contacts, COVID-19 Vaccine Providers, and Imms All Staff. I apologize for any duplications

Dear Immunization Partners,

Please share the following information with providers in your jurisdiction.

On April 22, 2023, the Centers for Disease Control and Prevention (CDC) updated their Interim Clinical Considerations for use of COVID-19 Vaccines Currently Authorized in the United States.

• Revisions to the mRNA COVID-19 vaccination schedule include:
• At the time of initial vaccination, depending on vaccine product, children ages 6 months through 4 years are recommended to receive 2 or 3 bivalent mRNA vaccine doses
• Children aged 5 years are recommended to receive 1 or 2 bivalent mRNA vaccine doses
• People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose
• People ages 65 years and older may receive 1 additional bivalent mRNA vaccine dose

Included in the clinical considerations are several detailed COVID-19 vaccination schedules sorted by COVID-19 vaccination history and age for people who are not moderately or severely immunocompromised. Information regarding the COVID-19 vaccination schedule for people who are moderately or severely immunocompromised has not been updated but will be available soon.

Updated resources are listed below:

Revised Pfizer-BioNTech Emergency Use Authorization (EUA) Fact Sheets:

• Healthcare Professional
  • Pfizer Bivalent Only Healthcare Providers 04182023 (michigan.gov)
• Recipients and Caregiver
  • Pfizer Bivalent Only Recipients and Caregivers 04182023 (michigan.gov)

Revised Moderna Emergency Use Authorization (EUA) Fact Sheets:

• Healthcare Professional
  • Moderna EUA Bivalent Only Healthcare Providers 04182023 (michigan.gov)
• Recipients and Caregiver
  • Moderna EUA Bivalent Only Recipients and Caregivers 04182023 (michigan.gov)

Alternatives to mRNA COVID-19 vaccines remain available for people who cannot or will not receive an mRNA vaccine. CDC’s recommendations for use of (monovalent) Novavax or Janssen’s COVID-19 vaccines were not affected by the changes.

CDC, ACIP, and MDHHS will continue to monitor COVID-19 disease levels and vaccine effectiveness in the months ahead and look forward to additional discussion around potential updates this fall.

COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. CDC recommends that people get up to date with COVID-19 vaccination as soon as feasible.

Your Immunization Outreach and Education Team,
Alyssa, Andrea, Dianne, Heidi, Lisa, and Sarah